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Abstract
Induced pluripotent stem cells (iPSCs) are expected to be a novel cell source for regenerative
medicine. Although iPSCs represented a significant breakthrough, there were many initial
obstacles for their clinical use such as exogenous sequence insertions, inefficient cell
reprogramming,  tumorigenic  properties,  and  animal-derived  culture  components.
However, much progress has been made in iPSC generation since their development. The
first human trial of iPSC-derived cell transplantation was conducted in September 2014,
in which iPSC-derived retinal pigment epithelial cells were transplanted to a patient with
macular degeneration. Because multiple clinical trials using iPSCs are expected in the
near future, preparation of guidelines for generating and selecting iPSC lines suitable for
clinical application is a pressing issue.
For clinical use of iPSCs, many examinations for evaluating iPSC lines must be conduct‐
ed  before  transplantation.  Different  combinations  of  reprogramming  factors,  gene
derivation vehicles, and types of donor cells can affect the quality of iPSCs, and guidelines
for selecting the most appropriate iPSC lines for clinical use are under development.
Furthermore, development of time- and cost-effective selection methods is essential for
expanding iPSC transplantation therapy. In this chapter, we review methods for preparing
human iPSCs before clinical use and the issues that are important for defining standard‐
ization of clinical-grade iPSCs.
Keywords: induced pluripotent stem cells, regenerative medicine, transplantation
therapy, standardization of stem cells, quality control of stem cells
1. Introduction
Induced pluripotent stem cells (iPSCs) are expected to be a novel cell source for regenerative
therapy [1, 2]. Their capacity for self-proliferation and multilineage potential is promising for
induction of regenerative cells without a natural capacity for self-renewal. In 2014, a ground‐
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breaking advance in iPSC research occurred when iPSC-derived sheets of retinal pigment
epithelium were transplanted to a patient with age-related macular degeneration, the first
report of iPSC treatment in humans [3]. Since then, explosive expansion clinical iPSC treatment
of patients with otherwise intractable diseases has been expected. However, expanding the
clinical use of iPSCs requires a well-defined quality standard. Generating clinical-grade iPSCs
for regenerative treatments presents many challenges, and concerns over safe iPSC use must
be solved promptly. For instance, ensuring that culture conditions are not exposed to risk of
contamination by predictable or unpredictable agents requires a great deal of investment in
terms of cost and equipment. In addition, the most clinically applicable method of generating
and selecting a suitable iPSC line is under debate. Furthermore, although the construction of
iPSC banks for allo-transplantation has progressed [4], generating sufficient qualified cell lines
for clinical use requires several years to cover a large segment of the population. In this chapter,
we discuss the current issues for expanding the clinical applications of human iPSCs.
2. Existing consensus guidelines for human pluripotent stem cells
In regard to the standardization of human pluripotent stem cells, a consensus for using
embryonic stem cells (ESCs) was previously announced by the International Stem Cell Banking
Initiative (ISCBI) contributors and the Ethics Working Party of the International Stem Cell
Forum [5]. This consensus defined general principles for human ESC banking and described
quality control processes for human ESC lines. Although many of these criteria can be applied
to iPSCs, standardization of iPSC lines for clinical application is not fully established because
there exist various iPSC generation methods and differences between iPSC lines. The tumori‐
genic and differentiation properties of iPSC lines are not identical, even for those generated
by the same procedure [6]. Therefore, to establish iPSC quality standards for clinical use,
determining which factors can affect iPSC quality and setting up requirements for clinical
application of iPSCs are critical issues. This challenge intrinsically questions whether iPSCs
can be equated with ESCs. To date, the existence of epigenetic differences between iPSCs and
ESCs has been shown [7], although these differences do not negate the applicability of iPSCs.
Recently, the previous consensus on human pluripotent stem cells was revisited with consid‐
eration of iPSCs [8]. However, international standardization of iPSC generation techniques
and quality verification is challenging. Many problems must be solved, including the scientific
validity of new insight into iPSCs, to determine their applicability to consensus guidelines. In
addition, these guidelines mainly target requirements for cell banking. In the case of iPSCs,
there will be clinical research using autogenic iPSCs similar to the first case in RIKEN [3].
Therefore, the number of institutions in which autogenic iPSCs are generated could increase
above the number of institutions for cell banking. Whether the institutional criteria for
generating autogenic iPSCs should be equal to those for cell banking remains vague. These
points should respectively be verified and adjusted based on scientific acceptability.
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3. Development of the definition of “clinical-grade iPSCs”
When human iPSCs are applied for clinical use as a transplantation cell source, the require‐
ments for iPSCs to satisfy clinical conditions must be validated in advance. Although most
provisions for “clinical-grade” iPSCs are associated with “safety,” this term encompasses
many elements at each stage of iPSC application to regenerative medicine. However, the most
suitable and the safest method for generating iPSCs for clinical use has not been defined
because experience in treating patients with iPSC-derived regenerative cells remains limited.
Therefore, to establish novel iPSC-based regenerative therapy, all factors that might affect
safety must be presented and discussed in each case.
For clinical application of iPSCs, safety is mainly divided into two considerations. The first is
that iPSCs must meet standards for general cell products. To establish iPSCs of clinical grade,
cell culture protocols must avoid any risk of contamination with unpredictable pathogens and
meet the standards for general cell products, such as good manufacturing practice (GMP) [5,
8]. Removing animal-derived products from the culture system is important for this purpose.
Furthermore, iPSCs and iPSC-derived cells must not include pathogens such as harmful
viruses or bacteria before clinical use. With respect to establishing cell culture protocols,
accurate sample identification must be provided throughout iPSC generation and differentia‐
tion. Therefore, to meet the standards for general cell products, the establishment of extensive
systems and equipment for culturing iPSCs is required.
The second aspect of safety is meeting the high quality standards for clinical applicability.
However, whereas standards for general cell products have been defined, standards for high-
quality iPSCs that meet applicability to clinical use remain vague. For example, methods for
denying the possible tumorigenicity of iPSCs and their derivatives remain undefined. In
addition, in the course of generating iPSCs, many steps affect iPSC quality. Worldwide
standardization of each stage of iPSC generation is desirable, but there are numerous problems
to be solved before achieving this goal.
4. Management of safety in each stage of iPSC generation
The first step for applying iPSCs application to clinical use is sampling somatic cells from
donors. Although this step appears simple, it already includes safety considerations. When
treatment with iPSCs is proposed, whether iPSCs are generated from the patient’s own somatic
cells or brought from a pool of allogeneic iPSCs such as the iPSC bank project [4] must be
decided. Using allogeneic iPSCs requires co-treatment with an immune suppressor and can
lead to a risk of malignant tumor and adverse effects. Generating autogenic iPSCs for each
patient is ideal, but it requires a tremendous cost and time investment. Particularly, if the
patient’s condition demands expediency, autogenic iPSCs might not be suitable. Even if
autogenic iPSCs are available, the appropriateness of applying quality standards for the
allogenic iPSC bank to autogenic iPSCs has to be considered. In addition, the choice of somatic
cell sources for iPSC generation is important. Naturally, invasive cell sampling is not prefera‐
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ble, but the type of original cells can affect iPSC features through the residual epigenetic status
of the original cells [9–12]. Therefore, this first step already requires evaluation of the appro‐
priate choice for each case.
The step following somatic cell sampling is somatic cell reprogramming. In this stage, the
suitability of the combination of reprogramming factors and gene introduction vehicles must
be verified. Although achievement of residual transgene-free iPSC lines was already estab‐
lished [13–19], the safest and most preferred type of gene vehicle and combination of reprog‐
ramming factors for clinical use are now in discussion. In addition, there are many reagent
options for culturing human iPSCs, and reagent selection must be verified in advance.
The next stage of clinical therapy using iPSCs is the induction of targeted cells from iPSCs.
iPSC lines do not exhibit identical points of differentiation [6, 12]. Although efficient induction
of intended differentiated cells and selection of suitable cell lines are important, ensuring the
safety of iPSC derivatives is a more important consideration. In particular, avoiding contam‐
ination of undifferentiated cells is essential for achieving clinical application. However,
methods for detecting residual undifferentiated cells also remain undefined. Selection of
appropriate iPSC lines is also important for avoiding tumorigenesis, which is known to differ
among cell lines [20].
After obtaining targeted cells for treatment, the method by which these cells are transplanted
is also associated with safety concerns. An appropriate transplantation protocol must be
examined and established in advance. In addition, establishment of safety nets for post-
treatment patients is also important.
Therefore, although the requirements for establishing a definitive standard for clinical-grade
iPSCs are unresolved, many points that affect the safety of treatments must be recognized and
appropriately verified before initiating treatment.
5. Advancement of reagents for iPSC generation and culture
As described above, meeting standards for general cell products is required for clinical use of
iPSCs. A culture condition for human pluripotent stem cells was first established for main‐
taining human ESCs [21] and contained several animal-derived products such as mouse
embryonic fibroblasts for feeder layers and fatal bovine serum in culture medium. This culture
system was applied to human iPSCs, and it successfully maintained their pluripotency and
self-proliferation [2]. Since then, toward realizing the clinical use of human iPSCs, the need for
an established, chemically defined condition for human iPSCs has attracted attention.
To this end, many researchers have challenged the removal of animal-derived feeder cells from
culture conditions. The initial condition for culturing human iPSCs contained mouse embry‐
onic fibroblasts or immortalized mouse fibroblasts such as SNL cells [2]. Although auto-
fibroblasts were applied and successfully served as alternative to animal-derived feeder cells
for human iPSC generation [22], the availability of human auto-fibroblasts is quantitatively
limited. Therefore, to apply human iPSCs to clinical use, replacing feeder layers with a
chemically defined substitute is required.
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Previously, gelatinous protein mixtures were applied to culturing human pluripotent stem
cells. For example, human ESCs were successfully maintained with Matrigel and chemically
defined medium [23]. Although Matrigel was applicable for maintenance of human pluripo‐
tent stem cells [24–26] and achieved feeder-free human iPSC generation [27, 28], this condition
was not animal product-free because the matrix is derived from Engelbreth-Holm-Swarm
mouse tumor [29] and contains many types of collagens, laminin, and proteoglycans. There‐
fore, the essential components for human iPSC culture have been investigated.
Other types of matrices, such as CellStart [30, 31] and synthetic polymers [32, 33], were tested
and successfully used as feeder cell substitutes for the maintenance and generation of human
pluripotent stem cells. In addition, recombinant cell adhesion proteins have received attention
as a defined alternative for feeder cells. For example, vitronectin is a glycoprotein present in
the extracellular matrix that mediates cell adhesion and was shown to be an alternative for
feeder cells in human pluripotent stem cell culture [34]. Laminin, a component of the basal
lamin, is another possible alternative to feeder cells in maintenance and generation of human
iPSCs [35, 36]. These products allow removal of animal-derived feeder layers from human
iPSC cultures and, therefore, are useful for establishing xeno-free culture conditions for human
iPSCs.
The initial culture medium for iPSCs also contained animal products such as fatal bovine
serum. There have been many subsequent reports of xeno-free media such as TeSR2 [37],
NutriStem [38], Essential E8 [34], and StemFit [39] for human iPSC generation and maintaining.
The combination of these matrices and media can achieve generation of human iPSCs under
completely defined conditions, thus making iPSC generation in xeno-free conditions achiev‐
able.
6. Choice of iPSC donor cell sources
There are two considerations when choosing the types of donor cells. The first is whether
allogenic iPSCs or autogenic iPSCs will be used. Applying autogenic iPSCs to each patient is
ideal because this method is not expected to require co-treatment with an immune suppressor
[40, 41]. The first case of therapy using iPSCs was performed using autogenic iPSCs [3] and
was important for reaffirming the usefulness of iPSCs as a source of autogenic regenerative
cells. Nevertheless, because of the immense amount of time and effort required to make
autogenic iPSCs from each patient, allogenic iPSCs that are matched in human leukocyte
antigen (HLA) type are an important option for establishing treatment with iPSC-derived cells
[4], especially in cases that demand expedient treatment. However, covering an entire
population with HLA-matched allogenic iPSCs is nearly impossible due to the high diversity
of HLA genes [42]. Therefore, to achieve complete coverage of the population with iPSC banks
is an important issue. In previous reports, hypoimmunogenic human pluripotent stem cells
were successfully generated through genome editing [43–45]. Although these methods could
complete the missing part of the iPSC bank, whether these genome-edited pluripotent cells
are safe needs further validation. At this time, the imperfect coverage of iPSC banks has to be
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recognized. When the time limit for generating iPSCs is not severe, autogenic iPSCs might
become an important option. Therefore, whether standard guidelines for clinical-grade iPSCs
can be defined equally for allogenic and autogenic iPSCs is in question. In a recent report,
contaminated undifferentiated iPSC-derived cells readily grew teratomas in syngeneic
conditions but not in allogenic conditions supported with an immune suppressor [46]. This
difference of tumorigenesis between iPSC derivatives in autogenic and allogenic conditions
could complicate definition of standards for clinical-grade iPSCs.
The other consideration about choosing types of donor cells is selection of the type of somatic
cells for reprogramming. To date, there have been many efforts to minimize the invasiveness
of sample acquisition. Previously, generating iPSCs from keratinocytes derived from plucked
hair [47], fibroblasts derived from oral mucosa [48], and peripheral blood cells obtained by
venipuncture [49–51] was established as less-invasive methods. However, the characteristics
of iPSCs can be affected by the type of somatic cells used for their generation [10–12]. Whether
residual epigenetic memory derived from original somatic cells is permissible in clinical-grade
iPSCs must be considered. In addition, although blood cells are becoming the preferred
material for iPSC generation, the best choice for generating iPSCs of high quality avoiding
capture of somatic mutations and aberrant epigenetic memory remains undefined. These
questions remain important issues toward standardization of iPSC quality.
7. Vehicles for gene delivery in iPSC generation
In generating iPSCs for clinical use, achieving residual transgene-free products is essential
because of the possibly harmful effect of residual transgenes. Since the first report of human
iPSC generation with retroviral gene introduction [2], there has been much technical progress
in methods of gene introduction for iPSC generation. Currently, methods of generating
transgene-free human iPSCs are established using adenovirus vectors [13], sendai virus vectors
[14], transposons [16], RNA [18], recombinant protein [15, 17], or episomal vectors [19]. Even
when non-viral methods such as episomal vectors are used, there is low incidence of genomic
insertion of exogenous sequence. In the case of viral vectors, transposons, and episomal
vectors, verification of vehicle elimination in iPSCs is necessary. Because methods for verifying
the removal of these vehicles are not identical in each case, unionization and standardization
of verification methods are difficult. An appropriate method must be established for each type
of vehicle, or whole-genome sequencing to detect aberrant vehicle-derived sequence insertions
might be essential for identifying residual transgene sequences in iPSCs.
8. Reprogramming factors and alternative molecules
In the first report of successful mouse somatic cell reprogramming with exogenous gene
introduction, forced expression of OCT3/4, SOX2, KLF4, and C-MYC was introduced into
mouse somatic cells [1]. Thereafter, although the resulting reprogramming efficiency was low,
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C-MYC was shown to be dispensable for somatic cell reprogramming [52]. Another study
showed that forced expression of OCT3/4, SOX2, LIN28, and NANOG also induced human
somatic cell reprogramming [53]. To date, there have been many efforts to generate high-
quality iPSCs, although the best combination of factors has not been established. To obtain safe
iPSCs, alternative genes for C-MYC are needed because C-MYC is an oncogenic gene [54], and
residual expression of C-MYC in iPSCs led to tumorigenesis [52]. TBX3 [55], L-MYC [56], and
GLIS1 [57] were reported as alternatives to C-MYC with improved chimerism, germline
contribution, or prognosis of iPSC-derived clone mice. Although replicating the chimerism
experiments using human iPSCs is difficult because of ethical problems, these alternatives to
C-MYC are expected to provide human iPSCs of high quality.
At the other extreme, there have been many efforts to generate iPSCs using chemical com‐
pounds. Although progress in developing gene vehicles enabled generation of residual
transgene-free iPSCs, the ultimate goal is to generate iPSCs without gene introduction. Many
previous reports demonstrated improved reprogramming efficiency with small molecules,
with some specific small molecules serving as a substitute for reprogramming factors [58].
Finally, in mice, a combination of small molecules completely reprogrammed somatic cells
into pluripotent states without forced expression of exogenous genes [59, 60]. Although these
chemically generated iPSCs require further verification in terms of quality such as residual
epigenetic modification of somatic cells, they have the potential to become mainstream for
iPSC-associated researches.
9. Quality control of iPSC lines
The quality of mouse iPSCs has been mainly evaluated through chimerism experiments [61].
Germline contribution of iPSCs and induction of iPSC-derived mice have been the ultimate
verifications of pluripotency. Previous reports of iPSC generation with TBX3 [55], L-MYC [56],
or GLIS1 [57] also evaluated the quality of iPSCs through mouse chimera formation and
germline contribution. However, these experiments are not applicable to human iPSCs because
of ethical concerns. In addition, although an in vivo teratoma formation assay has also been
used to establish the differentiation capacity of iPSCs, quantifying teratoma formation is rather
difficult in contrast to in vitro differentiation because the amount of time to teratoma formation
and pathological interpretation are needed. Therefore, the quality of human iPSCs has been
evaluated with an in vitro differentiation assay.
For example, the in vitro differentiation assay of human iPSCs revealed that differentiation
was affected by donor cell types [10–12]. This phenomenon is termed “epigenetic memory”
and, interestingly, does not arise from somatic cell reprogramming with nuclear transfer.
Although epigenetic memory decreases with increasing culture time [12], residual epigenetic
modification of iPSC origin cells must be considered when iPSCs are applied to clinical use.
In addition, the gene expression of iPSCs showing a tumorigenic tendency after neural
differentiation was analyzed [20], revealing that activated expression of genes containing
specific LTR7 sequences in iPSCs was statistically associated with tumorigenesis. Such
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predictive markers for the quality of human iPSCs are important for rapid selection of cell lines
suitable for clinical use.
Recent progress in next-generation sequencing (NGS) techniques has provided platforms for
exhaustive analysis of iPSC RNA, genome, and epigenome. This type of analysis can detect
chromosomal aberrations in human iPSCs as sequence abnormalities [62]. Although whether
somatic cell reprogramming itself can lead to genomic abnormalities in iPSCs is in discussion,
long-term culture of pluripotent stem cells is known to lead to genomic abnormalities [63].
Because mutations in protein-coding regions of the genome could trigger tumorigenesis of
iPSCs, analysis of iPSCs with NGS can assume a large role in evaluating iPSC quality and
selecting iPSCs suitable for clinical use.
As presented above, evaluation of human iPSC quality has been performed without chimera
assays. Whether all of perceptions in mouse iPSC experiments are directly applicable to human
iPSCs remains a matter of debate. Therefore, investigating the chimeric contribution capacity
of human iPSCs has an ultimate importance in quantifying the pluripotency of human iPSCs.
In this regard, recent analysis indicated the possibility of transcending boundaries between
human iPSCs and chimera formation assays. Human iPSCs and ESCs have features similar to
mouse epiblast stem cells, which are in an advanced differentiation state compared to mouse
ESCs [64]. Common human iPSCs and mouse epiblast stem cells are thought to be in a “primed
state” distinct from the “naïve state” of mouse ESCs. Pluripotent stem cells in a primed state
have difficulty in contributing chimeras in preimplantation embryos [65]. In addition,
generating chimeras of human and mouse cells is ethically problematic. Therefore, methods
for evaluating the quality of human iPSCs have not been standardized. However, a recent
report showed that human iPSCs could contribute to chimeras in stage-matched post-
implantation mouse embryos [66]. Although the observation period of chimeric embryos was
limited, chimera formation experiments with human iPSCs and stage-matching post-implan‐
tation mouse embryos might represent a novel assay for evaluating the quality of human iPSCs.
10. Quality control of iPSC-derived products
iPSCs are used as a cell source for inducing intended types of differentiated cells and are not
transplanted to patients directly. Therefore, as with quality control of iPSCs, quality control of
iPSC-derived products is important for ensuring the safety of clinical application of iPSCs and
contains two important considerations for achieving safety.
The first is purification of intended cells from a mixture of differentiated cells. Even a small
contamination of undifferentiated cells in the final product could lead to teratoma develop‐
ment after transplantation [67]. Therefore, appropriate methods for purification are required
to ensure safety. Purification of products derived from pluripotent stem cells has been
previously attempted using a surface marker of pluripotent stem cells to remove undifferen‐
tiated cells [68, 69] or cell sorting targeting surface markers specific to intended cells [70, 71].
However, fluorescence-activated cell sorting with cell surface markers is difficult to apply to
mass culture systems because of the large time investment required. To achieve applicability
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to mass culture systems, purification with medium conditions [72, 73] or with reagents with
specific cytotoxic effects against undifferentiated cells [74, 75] was developed. These techni‐
ques are expected to be useful for achieving safe iPSC-derived products.
To validate the quality of products derived from iPSCs, detection of residual undifferentiated
cells in the product is another essential technique for avoiding tumorigenesis after transplan‐
tation. If the methods described above for purification achieve high accuracy, methods for
evaluating the elimination of undifferentiated cells and assuring safety are required. However,
current validation methods for detecting residual undifferentiated cells in final products from
iPSCs are limited. Examining expression of pluripotent markers in products from iPSCs with
qRT-PCR [76, 77] and detecting specific glycoproteins in the cell culture supernatants [78] were
reported as useful methods for evaluating elimination of undifferentiated cells. To ultimately
demonstrate safety, the absence of tumorigenesis in in vivo transplantation assays is required,
but the appropriate observation period and numerous transplanted cells remain evasive. In
addition, whether xeno-transplantation experiments truly replicate transplantation of human
cases needs further validation.
11. Building safety nets for post-treatment patients
One of the most important issues for clinical iPSC application is the establishment of safety
nets for post-treatment patients. If tumorigenic cell contaminates the final iPSC-derived
product and might be transplanted into patients, measures to avoid health hazard to patients
must be established. Although surgical resection of iPSC-derived tumors is one conceivable
method, there will be cases that cannot be managed through surgery due to the invasiveness
of the operation.
Introducing a suicide system into human iPSCs before transplantation is another useful
approach for ensuring safe clinical application of iPSCs. When iPSC-derived tumors occur in
patients, ablation of iPSC-derived cells by switching the suicide system “on” can prevent
invasive surgery in high-risk patients. For example, herpes simplex virus thymidine kinase
(HSV-TK) phosphorylates ganciclovir (GCV) and leads to cytotoxicity in the presence of GCV.
HSV-TK has been widely used as “suicide gene” in human ESC experiments [79]. The
combination of HSV-TK and GCV was also tested in an in vivo mouse model with mouse iPSCs
[80, 81]. Another possibility is the combination of inducible caspase-9 and a chemical inducer
of dimerization, which was shown to work as suicide system in human iPSC derivatives [82].
Whereas the HSV-TK suicide system is cell cycle dependent, inducible caspase-9 achieves cell
cycle-independent ablation of target cells. Although these systems can become an important
option for treatment of iPSC-derived tumors, modified genomic introduction methods of
suicide genes are required for clinical use. Because random exogenous introduction using
lentiviral and retroviral vectors could break functional gene sequences in iPSCs, validation of
target sites for suicide gene insertion and targeted genome editing in iPSCs is required for
clinical application.
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This type of strategy has a disadvantage in that all iPSC-derived cells are diminished with the
suicide system. When iPSC-derived tumors occur, diminishing only tumor cells while
retaining the useful cells in the engrafted treatment is ideal. With this in mind, some reports
showed selective suicide systems in which the suicide gene is inserted under control of a
promoter of pluripotent markers [80]. However, in this area of research, how selective removal
of tumor cells should be ensured remains to be solved.
Currently, in contrast to research ensuring the safety of iPSCs and iPSC-derivatives, research
establishing methods to manage cases in which iPSC-derived tumors occur in post-treatment
patients is less common. To ensure safe clinical application of iPSCs, countermeasures for every
possible contingency after treatment using iPSCs must be prepared in advance. Thus, this type
of research is of considerable importance in the area of regenerative medicine.
12. Conclusion
iPSCs are expected to serve as a novel cell source for regenerative medicine, although there
are many points that require verification before expanding their application to broad clinical
uses. Standardization of iPSC quality is required, but current verification and validation
procedures are not perfect. This incompleteness must be widely recognized. To establish safe
iPSC use in regenerative therapy, appropriate improvements of these issues and defined
guidelines for iPSCs are expected.
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